GLOW Peptide Side Effects: What Is Reported, What Is Rare, and Who Should Avoid It

Serious adverse events are not commonly reported for GLOW or its components. The reporting system behind that statement is weaker for compounded medications than for approved drugs, so treat it as reassuring rather than conclusive.

GLOW is three peptides dissolved together in one 5 mL vial: 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500. Pepti's typical directions are 0.25 mL, which is 25 units on a U-100 insulin syringe, under the skin Monday through Friday mornings, so each dose delivers 2.5 mg GHK-Cu, 0.5 mg BPC-157 and 0.5 mg TB-500. Your physician sets your directions after reviewing your intake, and they are printed on the vial.

There is no side-effect data for the three together, because the blend has never been studied as a blend. What follows is what is reported clinically for GLOW and what the component safety pages describe. The full component detail is in is GHK-Cu safe, is BPC-157 safe and is TB-500 safe.

This is the part of GLOW's safety picture that separates it from the two-peptide BPC-157 + TB-500 stack. Copper is essential in small amounts and harmful in excess, and the liver is the body's route for excreting it.

This pattern is not reported at prescribed GHK-Cu doses in people with normal copper handling. It belongs to identifiable people: anyone with Wilson's disease, anyone whose liver cannot excrete copper normally, and anyone unknowingly taking two copper-containing products at once. Every GHK-Cu blend carries a full GHK-Cu dose, so GLOW alongside standalone GHK-Cu, KLOW, RADIANCE, REVIVE, ETERNAL or EUPHORIA doubles the copper. Your physician needs to see every product you are on before adding a second one.

High-dose zinc competes with copper absorption, and long-term high zinc intake is a recognised cause of copper deficiency. Injected copper bypasses the gut, so zinc does not block the injection, but your physician cannot judge your copper balance without knowing your zinc dose. Do not change your supplements on your own in either direction; tell your physician what you take.

If you think you may have taken too much, for example by drawing the wrong amount, call Poison Control at 1-800-222-1222 and message your care team. Do not skip, double or change a dose to compensate.

Not every side effect is urgent. Message your care team through your account for:

• Injection-site reactions that keep happening despite rotating sites.
• Nausea, light-headedness, headache or tiredness that has not settled after the first couple of weeks.
• A metallic taste, or nausea that seems to follow each dose.
• Any change in your medications or supplements, especially blood thinners, blood-pressure medication, zinc, or another product containing GHK-Cu.
• A new diagnosis, a pregnancy, or a planned surgery.
• A vial that looks different from the last one.

Your physician may revise your directions, change the product, or stop treatment. Do not change the dose yourself. When directions change, the new numbers are printed on the new label.

There is no established interaction list for GLOW or any component, because the trials that would produce one have not been run. That is why the intake asks for every medication and supplement you take, and why a physician reviews it rather than a form.

• Side effects of the three together. GLOW has never been studied as a combination, in people or in animals.
• Long-term human outcomes. No cohort has been followed for years on GLOW or any component by injection.
• Cumulative copper load from long-term injectable use. There is no published schedule for it.
• Whether the theoretical cancer concern is real. It is mechanistic reasoning, not an observed human signal, and it has not been ruled out.
• Immunogenicity rates. No study has measured how often any of the three produces antibodies.
• Subcutaneous pharmacokinetics in humans. Not measured for any of the three.

Each component is generally described as well tolerated in its own published animal work, and clinical reports on the blend are consistent with that: mostly injection-site reactions, sometimes early nausea or light-headedness. GHK-Cu has human topical data; BPC-157 has five small human studies that reported no serious adverse events, none of them using the subcutaneous route; TB-500 has none. The FDA's adverse-event database held no TB-500 reports through March 2025 and three uninterpretable reports for injectable BPC-157 through December 2025.

So the honest statement is narrow: short-term tolerability looks good where GLOW's components have been used, and long-term safety is not characterised. The separate and non-theoretical risk is supply. Research-use-only blends are sold openly with no pharmacy accountable for identity, purity, sterility or concentration, and the one reproducible adverse-event report in the FDA's database came from exactly such a product. The distinction is set out in research peptides vs prescription peptides.

Where the components stand with the FDA: all three were removed from Category 2 in April 2026; BPC-157 and TB-500 were recommended for the 503A Bulks List by the advisory committee in July 2026, with the final determination pending; GHK-Cu is scheduled for review before the end of February 2027. Compounded medications are not FDA approved, and GLOW is not an FDA-approved drug.

GLOW cannot be bought legitimately without a prescription. The prescription route:

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with ice packs, with sterile syringes, alcohol prep pads and your directions printed on the vial.
5. Your physician stays reachable for questions and side effects.

GLOW is $259 a month, all-in, covering medication, physician review, refill management and shipping, with no separate membership fee. Pepti is cash-pay and does not bill insurance. Refills run every 28 days, one vial per fill. Pepti prescribes GLOW in every state except Oklahoma, plus DC The full reference is what is GLOW, and how it compares with the KPV version is in KLOW vs GLOW.